In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized against respiratory syncytial virus (RSV). Nirsevimab administration ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting ...

A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates effectiveness against infections and associated hospitalizations in veterans aged 60 years or older during ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

Respiratory syncytial virus (RSV) is a common viral infection that may lead to serious complications in certain groups. Since 2023, vaccines are now available and are highly recommended ...

and respiratory syncytial virus are diagnosed – is currently "high" in the United States, according to an update from the Centers for Disease Control and Prevention. Currently, New Hampshire is ...

As the winter season continues, there's an increased chance of infections from COVID-19, influenza and respiratory syncytial virus. But, the U.S. Centers for Disease Control and Prevention ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the ...

caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and in individuals 50 through 59 who are at increased risk for LRTD caused by RSV. The data were presented as a ...